Study to Evaluate and Compare the Bioequivalence of Two Abaloparatide-sMTS Treatments in Healthy Women.

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 16, 2020

Primary Completion Date

February 9, 2021

Study Completion Date

August 13, 2021

Conditions
Osteoporosis
Interventions
COMBINATION_PRODUCT

abaloparatide-sMTS (Patheon)

single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes

COMBINATION_PRODUCT

abaloparatide-sMTS (Kindeva)

single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes

COMBINATION_PRODUCT

abaloparatide-sMTS (Patheon)

single-dose administration of abaloparatide 300 μg applied to the thigh for 4 minutes

COMBINATION_PRODUCT

abaloparatide-sMTS (Patheon)

single-dose administration of abaloparatide 300 μg applied to the thigh for 7 minutes

Trial Locations (1)

45227

Medpace Clinical Pharmacology, Cincinnati

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

Radius Health, Inc.

INDUSTRY